Pharma and Biotech organizations are facing growing challenges from the rapidly developing pharmacovigilance landscape and demands for the collection of more relevant safety data. These factors, combined with the pressure of cost containment, demand that life science organisations consider different approaches to the traditional, largely manual PV processes. A risk-based processing approach introduces a highly effective and efficient process to manage drug safety, ensuring quality data is collected across the portfolio, from newly launched to established products. In this presentation, we review the current PV landscape and outline how utilizing the latest technology approaches will: • Generate more consistent and relevant AE data • Support intelligent workflow from Affiliates to Central Safety teams • Improve ability to meet RMPs and REMS commitments • Enable greater visibility and control of the PV system • Enable immediate alerts/communication to reporters • Gain better understanding of medicines

2. •
•
•
•


•
•

3. •
•
•
•
•
•
•
•
•

4. •
•
•

5. •
•
0%
20%
40%
60%
80%
100%
Manufacturer
submitted -
Expedited
reports
Manufacturer
submitted -
Periodic
reports
Direct reports
by HCPs &
Patients
Incomplete
reports
Complete
reports

7. 2% 3% 1%
11%

8. 15%
5%
32%
4%
6%
5%
9%
12%
12%

9. •
•
•
•
•
•

11. .

14. •
•
•
•
•
•
•
•
•
•
•

17. •
•
•

18. •
•
•

19. •
•
•

20. •
•
•

21. 21